Tag Archives: Nicorandil

June 2016 Br J Cardiol 2016;23:56

Correspondence: Nicorandil, antithrombotic drugs, and non-variceal upper gastrointestinal bleeding

Ali S Taha, Caroline McCloskey, Wilson J Angerson

Abstract

Of the serious complications of gastrointestinal ulcers (bleeding, perforation, obstruction, and sometimes death), non-variceal upper gastrointestinal bleeding (NVUGIB) remains the commonest. These days it is mostly seen in association with the use of antithrombotic drugs (ATDs), particularly low-dose aspirin (75–325 mg/day), given for vascular protection.1 Nicorandil is a vasodilator that acts as a nitrate and K+ATP channel agonist. It is used in many countries worldwide and is often added to ATDs in the management of angina. In light of some case reports, its manufacturer and the medicines advisors and regulatory agencies have issued caut

| Full text

August 2012 Br J Cardiol 2012;19(Suppl 2):S2–S11 doi:10.5837/bjc.2012.s06

Chronic stable angina guidelines – is there an emerging international consensus?

Professor Jose Lopez-Sendon, Dr Henry Purcell, Professor Paolo Camici, Dr Caroline Daly, Professor Jamil Mayet, Dr John Parissis, Professor Francesco Pelliccia, Professor Christophe Piot, Professor Rainer Hambrecht

Abstract

Introduction Stable angina is the most common manifestation of coronary heart disease. While considered relatively benign in terms of prognosis, the condition confers a higher risk of cardiovascular events than in the general population, with average annual mortality rates of 1–2%. Guidelines for the management of stable angina are relatively conservative in their approach, given their process of development. Moreover, stable angina management has not been as rigorously evaluated in large randomised trials as other coronary conditions. The role of newer treatment options in management algorithms also merits wider consideration. This expert

| Full text

January 2004 Br J Cardiol 2004;11:65-8